Biopool Gets Approval to Sell Diagnostic Kit

Biopool International Inc. of Ventura received Food and Drug Administration approval to market its new Ristocetin Cofactor Assay Kit. The kit is used in the diagnosis of von Willebrand’s disease, a bleeding disorder similar to hemophilia.

Michael D. Bick, Biopool’s chief executive officer, estimated the worldwide market for the kit at $3 million to $5 million annually. “Only two other companies are known to be marketing such a test, and we expect to get a significant portion of the market,” he said.

Biopool produces a variety of kits used by hospitals and labs to test for blood and heart disorders.